Skip to content
Study details
Enrolling now

Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines

Northwell Health
NCT IDNCT07061847ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

40

Study length

about 2.3 years

Ages

18–75

Locations

1 site in NY

What this study is about

This trial is testing a new treatment to improve chronic migraine symptoms. The treatment involves an infusion of lidocaine into blood vessels in the skull to numb pain receptors, potentially reducing migraine intensity, frequency, and duration.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Lidocaine (drug)
  • 2.Undergo Lidocaine Procedure

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
topical

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

lidocaine, local anesthetic (Blocks sodium channels to numb tissue locally)

Drug routes

topical (Topical Cream)

Endpoints

Secondary: Adverse events at 24 hours and 3 months post-procedure., Mean change from baseline in the Global Assessment of Migraine Severity (GAMS) at 3 months, Sustained freedom from headache pain >48hrs.

Body systems

Neurology